https://www.contexttherapeutics.com/pubs daily 0.75 2025-11-21 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1499106209157-6PBR0ZEEV9MEAQR8JFEI/stock-photo-diferent-tablets-pills-capsule-heap-mix-therapy-drugs-doctor-flu-antibiotic-pharmacy-medicine-424979338.jpg News & Media https://www.contexttherapeutics.com/pubs/ct95-sitc2025 monthly 0.5 2025-11-11 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/0eb54fa0-e567-43ac-a046-d091c4b9c601/2025+CT-95+SITC+TIP+Poster.jpg News & Media - A Phase 1, First-in-Human Study of CT-95, a Mesothelin-Directed Bispecific T Cell Engager (TCE) in Subjects with Advanced Solid Tumors - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.contexttherapeutics.com/pubs/ct202-sitc2025 monthly 0.5 2025-11-11 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/d66f2888-fdd9-49f7-9400-b3b796c7489c/CT-202-SITC25+Poster_2025+11+11.jpg News & Media - CT-202: a Dual pH-dependent Nectin-4xCD3 Bispecific T Cell Engager - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.contexttherapeutics.com/pubs/2025/11/21/context-therapeutics-reports-third-quarter-2025-operating-and-financial-results monthly 0.5 2025-11-21 https://www.contexttherapeutics.com/pubs/ctim-sitc2024-xjhc2-kkey2 monthly 0.5 2025-10-30 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/e036284e-96f0-4e8b-bb73-e99f00435cca/1748637156022-4c7fd85e-1c99-4c7d-84d6-99668b9e4974_1.jpg News & Media - A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurrent Ovarian Cancer and Other Advanced Solid Tumors - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.contexttherapeutics.com/pubs/ctim-sitc2024-xjhc2 monthly 0.5 2025-04-28 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/a49c28d7-7d6d-406e-bc30-51de2adc0317/Context+Therapeutics+AACR+2025+Final.jpg News & Media - Determination of first in human dose of the T cell-redirecting bispecific antibody CT-95 targeting mesothelin and CD3 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.contexttherapeutics.com/pubs/ctim-sitc2024 monthly 0.5 2025-04-28 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/23e94c7b-66bf-4915-bb5b-f02d1e5095cf/SITC2024.png News & Media - Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.contexttherapeutics.com/pubs/ctim-sitc2023 monthly 0.5 2025-04-28 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/2f3833c3-bd3a-49a0-9b14-611ae56af8e3/20231019+-+SITC+-+CTIM-76+Poster+-+FINAL.jpg News & Media - CTIM-76, a Highly Specific Claudin 6 Antibody - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.contexttherapeutics.com/pubs/ctim-aacr2023 monthly 0.5 2025-04-28 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1686073478321-L5NT0ITVXI5GWN1D395M/2023_AACR_MPS+CLDN6+bispecifics1024_1.jpg News & Media - Development of CTIM-76, a highly specific Claudin 6 bispecific antibody for treatment of ovarian cancer https://www.contexttherapeutics.com/pubs/ctim-aacr2022 monthly 0.5 2024-05-16 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1686074214009-5THX9FUC1L7I1W44F2S2/2022_AACR_MPS+Final1024_1.jpg News & Media - Atomic-level Specificity of Claudin 6 Monoclonal Antibodies Isolated for Treating Solid Tumors https://www.contexttherapeutics.com/pubs/2022/3/8/context-therapeutics-announces-acceptance-of-five-abstracts-to-be-presented-at-the-american-association-for-cancer-research-aacr-annual-meeting-2022 monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2021/8/25/context-therapeutics-and-tyligand-bioscience-reach-ona-xr-manufacturing-optimization-milestone monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2021/5/11/context-therapeutics-and-jefferson-health-announce-first-patient-dosed-in-phase-2-trial-of-ona-xr-in-advanced-endometrial-cancer monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2021/4/8/nbspcontext-therapeutics-and-integral-molecular-enter-collaboration-and-license-deal-for-novel-claudin-6-antibodies-for-gynecologic-cancer-therapeutic-program monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2021/3/22/context-therapeutics-expands-board-of-directors monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2020/3/12/tyligand-bioscience-and-context-therapeutics-sign-strategic-development-agreement-for-onapristone-er-hwzwn-xabn4-pwb26-ztrhp-cw58b monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2020/3/12/tyligand-bioscience-and-context-therapeutics-sign-strategic-development-agreement-for-onapristone-er-hwzwn-xabn4-pwb26-ztrhp monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2020/3/12/tyligand-bioscience-and-context-therapeutics-sign-strategic-development-agreement-for-onapristone-er-hwzwn-xabn4-pwb26 monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2020/9/ceo-ey-2020-finalist monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2020/3/12/tyligand-bioscience-and-context-therapeutics-sign-strategic-development-agreement-for-onapristone-er-hwzwn monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2018/12/8/the-pure-progesterone-receptor-pr-antagonist-onapristone-enhances-the-anti-proliferative-effects-of-cdk46-inhibitors-and-fulvestrant-a-serd-in-preclinical-in-vitro-breast-cancer-models-zssjr monthly 0.5 2024-05-16 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1593439757119-4S5S1I5P69ZNHGTRUJDB/0001.jpg News & Media - Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1593439755687-4L6PS533IPJUCHX0PBIT/0002.jpg News & Media - Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1593439751216-POGL9XE4YG7913JIHOU5/0003.jpg News & Media - Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1593439753666-EOEVXANOO7R3AS8R0AXB/0004.jpg News & Media - Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1593439750437-CUEY39GOQZJYT9FINMQ1/0005.jpg News & Media - Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1593439769695-YEW741GKHDB6JTRTOSRJ/0006.jpg News & Media - Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1593439775797-RX6F6NPCSPHQ1GHTN2EI/0007.jpg News & Media - Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1593439777190-C3SC6WXBYL5XPKBHPF3D/0008.jpg News & Media - Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1593439762390-RMGFVVJBEIJFUT1BZ34M/0009.jpg News & Media - Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1593439770170-6J58QQFL8BPKD91CGQBF/0010.jpg News & Media - Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1593439759817-FF16WKPQLNUG8WTXRKEH/0011.jpg News & Media - Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity https://www.contexttherapeutics.com/pubs/2020/3/12/tyligand-bioscience-and-context-therapeutics-sign-strategic-development-agreement-for-onapristone-er monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2020/3/4/leaning-into-investigator-sponsored-trials monthly 0.5 2024-05-16 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1583331002428-RXIZ920JSLWVA5R7MAP8/Table+1.jpg News & Media - Leaning Into Investigator Sponsored Trials https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1583331083518-J8XTJAQA0XE3VFY6GF0C/Table+2.jpg News & Media - Leaning Into Investigator Sponsored Trials https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1583331159553-MSWN0IFNBNUO2SR6BS4H/Figure+1.jpg News & Media - Leaning Into Investigator Sponsored Trials https://www.contexttherapeutics.com/pubs/2019/12/30/lifescienceleader-epyrf monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2020/1/7/context-therapeutics-to-present-at-biotech-showcase-2020 monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2019/12/30/lifescienceleader monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/10/7/wisconsinoncologynetwork-lnnws monthly 0.5 2024-05-16 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1572378221757-KC386YFFYFIMIVY07Z7R/john-george_145xx1016-1355-0-0.png News & Media - Why this Philadelphia cancer therapy developer is taking a clinical testing path less traveled By John George – Senior Reporter, Philadelphia Business Journal https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1572377893744-14Y6UG67N2WYYU91FG2M/RBF_7070.jpg News & Media - Why this Philadelphia cancer therapy developer is taking a clinical testing path less traveled Context Therapeutics CEO Martin Lehr founded the company in 2016. https://www.contexttherapeutics.com/pubs/10/7/wisconsinoncologynetwork monthly 0.5 2024-05-16 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1570457046335-DRBSFSRG5HDF0WMFJKK7/20191007+WON+Announcement.jpg News & Media - Context Therapeutics and Wisconsin Oncology Network (WON) to Evaluate Apristor Combination Therapy for Women with Advanced Breast Cancer https://www.contexttherapeutics.com/pubs/2019/9/18/jefferson-endometrial-bhattacharya monthly 0.5 2024-05-16 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1568745092869-JCB19MWPLNFW6549K4PU/20190917+TJU+Announcement.png News & Media - Context Therapeutics and Thomas Jefferson University to Evaluate Apristor Combination Therapy for Women with Advanced Endometrial Cancer https://www.contexttherapeutics.com/pubs/2019/9/16/onawa-study-announcement monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2019/5/2/context-therapeutics-and-world-renowned-cancer-center-announce-a-phase-2-trial-for-apristor-in-progesterone-receptor-positive-gynecological-cancers monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2019/3/19/context-to-participate-in-upcoming-investor-conferences-in-april monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2018/11/13/context-announces-presentation-of-new-preclinical-data-on-apristor-in-combination-with-a-cdk46-inhibitor-at-san-antonio-breast-cancer-symposium-bs44s monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2018/12/17/context-therapeutics-announces-key-additions-to-its-board-of-directors monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2018/12/8/context-therapeutics-announces-new-preclinical-data-on-apristor-at-san-antonio-breast-cancer-symposium monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2018/12/8/the-pure-progesterone-receptor-pr-antagonist-onapristone-enhances-the-anti-proliferative-effects-of-cdk46-inhibitors-and-fulvestrant-a-serd-in-preclinical-in-vitro-breast-cancer-models monthly 0.5 2024-05-16 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1544210567512-EI39OGV7XKNNIMHGRFCR/SABCS2018_Apristor_Cdk4-6+Combo_Poster.png News & Media - The pure progesterone receptor (PR) antagonist onapristone enhances the anti-proliferative effects of CDK4/6 inhibitors and fulvestrant, a SERD, in preclinical in-vitro breast cancer models https://www.contexttherapeutics.com/pubs/2018/11/13/context-announces-presentation-of-new-preclinical-data-on-apristor-in-combination-with-a-cdk46-inhibitor-at-san-antonio-breast-cancer-symposium monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2018/10/10/context-reports-encouraging-phase-1-safety-and-efficacy-data-of-apristor monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2018/9/13/ceo-martin-lehr-featured-in-life-science-leader-magazine monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2018/8/8/context-therapeutics-signs-strategic-research-collaborations-for-apristor-with-leading-breast-cancer-investigators monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2018/4/27/ceo-martin-lehr-named-ernst-young-2018-entrepreneur-of-the-year-semifinalist monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2018/8/9/interview-with-scott-applebaum-president-of-context-therapeutics-part-iii-71318 monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2018/1/16/context-therapeutics-announces-the-acquisition-of-apristor-onapristone-xr monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2018/1/15/phillys-context-therapeutics-will-now-test-prostate-cancer-drug-on-breast-cancer monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2017/11/16/context-therapeutics-announces-senior-leadership-appointments monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2017/11/15/chemdiv-context-therapeutics-and-torrey-pines-investment-announce-co-development-agreement monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2017/11/19/small-molecule-sigma1-modulator-induces-autophagic-degradation-of-pd-l1 monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2017/11/19/introduction-to-sigma-proteins-evolution-of-the-concept-of-sigma-receptors monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2017/10/12/drexel-researcher-nominated-as-prestigious-2017-stat-wunderkind monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2017/8/17/context-therapeutics-initiates-collaborations-with-three-leading-research-partners-on-the-biology-of-sigma1 monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2017/6/27/sigma1-pharmacology-in-the-context-of-cancer monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2017/6/27/researchers-at-sidney-kimmel-cancer-center-at-thomas-jefferson-university-promise-new-directions-for-targeting-prostate-cancer monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2017/6/27/novel-small-molecule-sigma1-inhibitors-for-advanced-prostate-cancer monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2017/7/10/invented-at-drexel-startup-companies-to-showcase-new-drug-treatments-at-the-coulter-investment-forum monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/2017/6/27/sigma1-targeting-to-suppress-aberrant-androgen-receptor-signaling-in-prostate-cancer monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/pubs/category/News+Releases monthly 0.5 https://www.contexttherapeutics.com/pubs/category/Publications monthly 0.5 https://www.contexttherapeutics.com/pubs/category/Context+In+The+News monthly 0.5 https://www.contexttherapeutics.com/pubs/tag/CLDN6 monthly 0.5 https://www.contexttherapeutics.com/pubs/tag/Nectin monthly 0.5 https://www.contexttherapeutics.com/pubs/tag/MSLN monthly 0.5 https://www.contexttherapeutics.com/team-bios daily 0.75 2026-01-26 https://www.contexttherapeutics.com/team-bios/andy-pasternak monthly 0.5 2025-01-13 https://www.contexttherapeutics.com/team-bios/jennifer-evans-bgsdk monthly 0.5 2025-09-10 https://www.contexttherapeutics.com/team-bios/jennifer-evans-bgsdk-xnf7p monthly 0.5 2025-06-03 https://www.contexttherapeutics.com/team-bios/christopher-beck monthly 0.5 2024-08-07 https://www.contexttherapeutics.com/team-bios/butz monthly 0.5 2024-08-13 https://www.contexttherapeutics.com/team-bios/chagin-karen monthly 0.5 2025-11-14 https://www.contexttherapeutics.com/team-bios/claudio-hb38b monthly 0.5 2025-11-14 https://www.contexttherapeutics.com/team-bios/cooper-lisa monthly 0.5 2025-11-14 https://www.contexttherapeutics.com/team-bios/claudio-6xxhk monthly 0.5 2026-01-21 https://www.contexttherapeutics.com/team-bios/claudio-6xxhk-nwy7e monthly 0.5 2026-01-21 https://www.contexttherapeutics.com/team-bios/jennifer-evans monthly 0.5 2025-04-07 https://www.contexttherapeutics.com/team-bios/philip-kantoff monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/team-bios/martin-lehr monthly 0.5 2025-05-06 https://www.contexttherapeutics.com/team-bios/2017/7/4/jane-doe-enlzy-f2mf4-nr6fw-h3edt-fcysz-f73b8-jla2a-fg7rx-nt3zy-jx2r9-xjy7r-bpeps-25rss-4zwpm-7cek4 monthly 0.5 2025-01-16 https://www.contexttherapeutics.com/team-bios/martin-lehr-cfbtt monthly 0.5 2025-01-16 https://www.contexttherapeutics.com/team-bios/alevit monthly 0.5 2024-08-08 https://www.contexttherapeutics.com/team-bios/christopher-beck-xw2h9 monthly 0.5 2025-08-07 https://www.contexttherapeutics.com/team-bios/jennifer-minai monthly 0.5 2024-08-07 https://www.contexttherapeutics.com/team-bios/karenandreas-3alcy-xrz4t monthly 0.5 2025-04-01 https://www.contexttherapeutics.com/team-bios/karenandreas monthly 0.5 2025-05-13 https://www.contexttherapeutics.com/team-bios/karenandreas-3alcy-yt3a9 monthly 0.5 2025-05-13 https://www.contexttherapeutics.com/team-bios/jwest monthly 0.5 2026-01-26 https://www.contexttherapeutics.com/team-bios/ezebrow monthly 0.5 2026-01-26 https://www.contexttherapeutics.com/team-bios/2021/7/linda-west monthly 0.5 2024-05-16 https://www.contexttherapeutics.com/team-bios/category/Directors monthly 0.5 https://www.contexttherapeutics.com/team-bios/category/Advisors monthly 0.5 https://www.contexttherapeutics.com/team-bios/category/Team monthly 0.5 https://www.contexttherapeutics.com/abstracts-and-posters daily 0.75 2024-05-17 https://www.contexttherapeutics.com/abstracts-and-posters/2019/aacrposter2625 monthly 0.5 2019-04-08 https://www.contexttherapeutics.com/abstracts-and-posters/2019/3/21/apristor-poster-926-onapristone-enhances-the-anti-proliferative-effects-of-cdk46-inhibitors-in-preclinical-in-vitro-breast-cancer-models monthly 0.5 2019-03-21 https://www.contexttherapeutics.com/abstracts-and-posters/category/Abstract monthly 0.5 https://www.contexttherapeutics.com/abstracts-and-posters/category/Poster monthly 0.5 https://www.contexttherapeutics.com/management daily 0.75 2023-11-14 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1526069200604-LZ6N4KJJCUWMQ3UNW6IG/Team.jpg Management https://www.contexttherapeutics.com/contact daily 0.75 2023-10-13 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1526302792568-AKYZ5DB4CX8IWIW2JNOI/Pipeline.jpg Contact https://www.contexttherapeutics.com/directors daily 0.75 2019-10-29 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1526069350008-A31U39G92SCN8662F7AH/Team.jpg Directors https://www.contexttherapeutics.com/advisors daily 0.75 2023-11-14 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1526069438304-ZST3XGFC7EVW4XRXNFEW/Team.jpg Advisors https://www.contexttherapeutics.com/publications daily 0.75 2025-11-22 https://www.contexttherapeutics.com/pipeline daily 0.75 2025-11-29 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/4453b82a-cff1-4c14-949f-fe25de6e12b1/Pipeline.png https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/4629a805-9033-4f71-b639-956a1ce90c18/CTIM76.png https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/22071b8d-a33c-465c-8d6e-c06a1a373767/CT95.png https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/781780d3-65fb-443b-8b02-c2343998cc58/CT202.png https://www.contexttherapeutics.com/privacy-policy daily 0.75 2026-01-15 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1526304452372-0WEVG70VKQ8I7JG5DE7K/203864.png Privacy Policy https://www.contexttherapeutics.com/terms-of-use daily 0.75 2023-11-13 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1526304865568-4V8FGH3A2AGDIJ75B8YO/203864.png Terms of Use https://www.contexttherapeutics.com/expanded-access daily 0.75 2026-03-31 https://www.contexttherapeutics.com/ist daily 0.75 2018-09-26 https://www.contexttherapeutics.com/more-info-onward-220 daily 0.75 2022-01-14 https://www.contexttherapeutics.com/more-info-onward-203 daily 0.75 2021-05-24 https://www.contexttherapeutics.com/more-info-elona daily 0.75 2023-02-01 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1560280828434-YD426SFKFXXI1IX44AI2/Simple%2BMOA.jpg More Info - ELONA https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1560280828434-YD426SFKFXXI1IX44AI2/Simple%2BMOA.jpg More Info - ELONA https://www.contexttherapeutics.com/our-values-1 daily 0.75 2024-05-17 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1556326868725-C9W51G1S9455MG83YYHN/iconfinder_globe_network_earth_planet_communication_web_worldwide_1079608+%281%29.png Values - Learn More https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1556326868725-C9W51G1S9455MG83YYHN/iconfinder_globe_network_earth_planet_communication_web_worldwide_1079608+%281%29.png Values - Learn More https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1556323546520-D423V6JW1VZDYYWANASH/iconfinder_businessman_ways_direction_choice_question_search_alternative_1079672.png Values - Learn More https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1556323581580-Q6FJZE5SQKNIMM98BGUF/iconfinder_businessmen_gears_idea_creative_organization_teamwork_partnership_1076682.png Values - Learn More https://www.contexttherapeutics.com/rare daily 0.75 2022-12-13 https://www.contexttherapeutics.com/more-info-onward-221 daily 0.75 2022-01-14 https://www.contexttherapeutics.com/more-info-onward-202 daily 0.75 2022-01-14 https://www.contexttherapeutics.com/more-info-smile daily 0.75 2022-08-02 https://www.contexttherapeutics.com/ctim76 daily 0.75 2025-11-25 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1617803465600-JFGV4XV2DM8CAX9NSFEQ/Bi%2BImage.jpg CTIM-76 https://www.contexttherapeutics.com/careers daily 0.75 2026-03-31 https://www.contexttherapeutics.com/patients daily 0.75 2025-11-25 https://www.contexttherapeutics.com/onward-201 daily 0.75 2024-05-16 https://www.contexttherapeutics.com/home daily 1.0 2026-01-30 https://www.contexttherapeutics.com/partnering daily 0.75 2024-10-21 https://www.contexttherapeutics.com/cldn6 daily 0.75 2024-09-23 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/561318ae-c173-4376-9d5c-bc5b1f6052e8/CLDN6+transmembrane.png Claudin 6 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/03aa40e7-92ec-45a9-9411-94bb7ad60cd1/TCGA.png Claudin 6 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/d14258fa-ffaf-4647-a008-21d9919af32f/Kojima.jpg Claudin 6 5-Year Survival Rates https://www.contexttherapeutics.com/about-us daily 0.75 2026-01-21 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/1556127249231-NOZCWNP5UFYM96H43OGT/teamwork.png https://www.contexttherapeutics.com/clin-ops-cta daily 0.75 2024-12-13 https://www.contexttherapeutics.com/exec-dir-quality daily 0.75 2026-02-02 https://www.contexttherapeutics.com/ct95 daily 0.75 2025-10-30 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/10f319f9-98a5-44c8-85ee-68441342edc3/Picture1111.png CT-95 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.contexttherapeutics.com/ct202 daily 0.75 2025-11-20 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/478b7bed-4cc8-44ad-84ee-1a2b71952453/Image+5364.jpg CT-202 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.contexttherapeutics.com/clin-ops-ctm daily 0.75 2024-12-13 https://www.contexttherapeutics.com/clin-reg daily 0.75 2024-12-13 https://www.contexttherapeutics.com/clin-ops-data-mgmt daily 0.75 2024-12-13 https://www.contexttherapeutics.com/strat-source daily 0.75 2024-12-13 https://www.contexttherapeutics.com/reg-aug2025 daily 0.75 2025-09-02 https://www.contexttherapeutics.com/sr-dr-clin-dev daily 0.75 2025-09-12 https://www.contexttherapeutics.com/sandbox-pipeline daily 0.75 2025-11-21 https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/e32ccf49-57bd-4dcf-b894-59cafcfe471e/AroHa_02.jpg https://www.contexttherapeutics.com/our-technology daily 0.75 2025-12-01 https://images.squarespace-cdn.com/content/v1/594a6b28e110ebf39e053038/e7bc7505-b377-4fc4-a6cc-146f868152a4/TCE+MOA+for+Website.png https://www.contexttherapeutics.com/officer-manager daily 0.75 2026-02-23 https://www.contexttherapeutics.com/exec-dir-ex-mgfr daily 0.75 2026-03-31